Lau Christine Sm, Mahendraraj Krishnaraj, Chamberlain Ronald S
Department of Surgery, Saint Barnabas Medical Center, Livingston, NJ, USA.
Saint George's University School of Medicine, Grenada, West Indies.
Cancer Manag Res. 2017 May 2;9:159-166. doi: 10.2147/CMAR.S117799. eCollection 2017.
Oligodendrogliomas (OGs) account for <20% of all intracranial tumors and 25% of gliomas. Despite improvements in imaging techniques allowing for earlier diagnosis, OG is rare among the pediatric population. This study examines a large cohort of OG patients in an effort to define the demographic, clinical, and pathologic factors associated with clinical and survival outcomes.
Data on 7,001 OG patients were abstracted from the Surveillance, Epidemiology, and End Result (SEER) database (1973-2013). Pediatric patients were defined as ≤19 years old, and adult patients were defined as age ≥20 years.
Among 7,001 OG patients, 6.5% were pediatric (mean age 12 ± 6 years), and 93.5% were adult (mean age 46 ± 15 years). Overall, OGs were more common among males, with a male-to-female ratio of 1.28:1. Overall, OGs were more common among Caucasians (76.9%) and also among the African American (10.8% pediatric vs. 4.0% adult) and Hispanic (12.8% pediatric vs. 11.8% adult). OGs occurred most commonly in the temporal lobe of pediatric patients and the frontal lobes of adults. Surgical resection was the primary treatment modality for both pediatric and adult populations (70.6% and 40.5%), followed by combined surgery and radiation (19.7% and 41.2%). Surgical resection was associated with significantly improved survival in both groups. Pediatric patients had a lower overall mortality (19.8% vs. 48.5%) and lower cancer-specific mortality (17.6% vs. 36.8%).
OGs most often present in Caucasian males in their fifth decade of life with tumors >4 cm in size. Children typically present with tumors in the temporal lobe, while adults present with tumors in the frontal lobe. Surgical resection confers a survival advantage among all patients, especially pediatric patients. Overall survival (OS) and cancer-specific survival are higher in the pediatric population. Further studies on novel treatment techniques, including bevacizumab and immunotherapy approaches, are required.
少突胶质细胞瘤（OGs）占所有颅内肿瘤的比例不到20%，占胶质瘤的25%。尽管成像技术有所改进，能够实现更早诊断，但OG在儿科人群中仍很罕见。本研究对一大群OG患者进行了检查，以确定与临床和生存结果相关的人口统计学、临床和病理因素。
从监测、流行病学和最终结果（SEER）数据库（1973 - 2013年）中提取了7001例OG患者的数据。儿科患者定义为年龄≤19岁，成人患者定义为年龄≥20岁。
在7001例OG患者中，6.5%为儿科患者（平均年龄12±6岁），93.5%为成人患者（平均年龄46±15岁）。总体而言，OG在男性中更为常见，男女比例为1.28:1。总体而言，OG在白种人中更为常见（76.9%），在非裔美国人中也较为常见（儿科患者中占10.8%，成人患者中占4.0%）以及西班牙裔中（儿科患者中占12.8%，成人患者中占11.8%）。OG最常发生在儿科患者的颞叶和成人的额叶。手术切除是儿科和成人患者的主要治疗方式（分别为70.6%和40.5%），其次是手术联合放疗（分别为19.7%和41.2%）。手术切除与两组患者的生存率显著提高相关。儿科患者的总体死亡率较低（19.8%对48.5%），癌症特异性死亡率也较低（17.6%对36.8%）。
OG最常出现在50岁左右的白种男性中，肿瘤大小>4 cm。儿童通常表现为颞叶肿瘤，而成人表现为额叶肿瘤。手术切除对所有患者，尤其是儿科患者，具有生存优势。儿科人群的总生存期（OS）和癌症特异性生存期更高。需要对包括贝伐单抗和免疫治疗方法在内的新型治疗技术进行进一步研究。
